NCT03350178

Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: MaaT Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

ICU patient's complications are notably due to multiple infections with high risks of sepsis. Those infections would be worsened by any antibiotic resistance mechanism. Thus, reducing MDR portage in health care unit is a global strategy that will benefit for the patients and the health system organization. Fecal Microbiota transfer and restoration is a promising strategy to achieve this purpose.

Conditions

• Intensive Care Units
• Fecal Microbiota Transplantation

Interventions

Type	Name	Description
DRUG	fecal microbiota transfer	transfer of fecal microbiota from healthy donor to the patients

Timeline

• Start date: 2018-01-15
• Primary completion: 2019-02-19
• Completion: 2019-02-19
• First posted: 2017-11-22
• Last updated: 2019-03-08

Locations

2 sites across 1 country: France